Clinical Trials Sponsored by JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Total 998 results

JANSSEN Alzheimer Immunotherapy Research & Development...

Terminated

AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Terminated

Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab

Alzheimer Disease

United States
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer Disease

United States
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Japan
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease

Alzheimer Disease

Japan
JANSSEN Alzheimer Immunotherapy Research & Development...
Pfizer

Terminated

Retrieval of Patient Information After Discontinuation (RAPID)

Alzheimer's Disease
JANSSEN Alzheimer Immunotherapy Research & Development...
Pfizer

Completed

Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease (ACCTION)

Alzheimer's Disease

United States
JANSSEN Alzheimer Immunotherapy Research & Development...
Pfizer

Completed

Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease (SUMMIT AD)

Alzheimer's Disease

United States
JANSSEN Alzheimer Immunotherapy Research & Development...
Pfizer

Terminated

A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States, Canada, Austria
JANSSEN Alzheimer Immunotherapy Research & Development...
Pfizer

Completed

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)

Alzheimer's Disease

United States, Germany, Canada, Austria
JANSSEN Alzheimer Immunotherapy Research & Development...
Pfizer

Completed

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)

Alzheimer's Disease

United States
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

Alzheimer's Disease

United States, Korea, Republic of
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Terminated

A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease

Alzheimer Disease

United States
JANSSEN Alzheimer Immunotherapy Research & Development...
Pfizer

Completed

AAB-001 in Patients With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer Disease

Spain, France, Germany
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Korea, Republic of, United States
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease

Alzheimer's Disease

United States
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Terminated

Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Japan
Pfizer
Janssen Alzheimer Immunotherapy (JAI) Research and Development, LLC

Completed

Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer Disease

Spain, France, Germany
JANSSEN Alzheimer Immunotherapy Research & Development...
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease

Alzheimer's Disease

United States
Janssen Research & Development, LLC

Not yet recruiting

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer (MoonRISe-1)

Non-Muscle Invasive Bladder Cancer

Czechia
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-87890387 for Advanced Solid Tumors

Advanced Solid Tumors

United States
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

Neoplasms | Myeloproliferative Disorders | Essential Thrombocythemia | Myelofibrosis

United States, Canada
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer

Lymphoma, Non-Hodgkin

Denmark, Israel, Spain, Australia
Janssen Research & Development, LLC

Recruiting

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (COCOON)

Carcinoma, Non-Small-Cell Lung

United States, Taiwan, Korea, Republic of, Malaysia, Turkey, Spain, China, Argentina
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet) (ICONIC-TOTAL)

Plaque Psoriasis

United States, Korea, Republic of, United Kingdom, Taiwan, Canada, Spain, Poland, Turkey, Germany, Hungary, Argentina
Janssen Research & Development, LLC

Recruiting

A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer (PolyDamas)

Carcinoma, Non-Small-Cell Lung

Korea, Republic of, United States, Malaysia, Turkey
Janssen Research & Development, LLC

Recruiting

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-9)

Relapsed or Refractory Multiple Myeloma

United States, Canada, Australia, China, Germany, Belgium, Malaysia, Turkey, Japan, Israel, Sweden, Spain, United Kingdom, Czechia, Denmark, Brazil, Italy, France, Netherlands, Poland, Austria, Portugal, Greece, India
Janssen Research & Development, LLC

Recruiting

A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy (VENTURA-1)

Anhedonia | Depressive Disorder, Major

United States, Spain, Bulgaria, Italy, Poland, Belgium, Argentina, Czechia, Hungary, Sweden, Brazil, Australia, Portugal
Janssen Research & Development, LLC

Recruiting

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment (MonumenTAL-3)

Relapsed or Refractory Multiple Myeloma

United States, Belgium, Korea, Republic of, Italy, Taiwan, China, Germany, Israel, Turkey, Japan, France, United Kingdom, Czechia, Brazil, Spain, Poland, Netherlands, Greece
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

Leukemia, Myeloid, Acute

United States, Germany, Italy, France, Australia, Spain, United Kingdom
Janssen Research & Development, LLC

Recruiting

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

Urinary Bladder Neoplasms | Receptors, Fibroblast Growth Factor

Korea, Republic of, United States, Germany, Spain, Netherlands
Janssen Research & Development, LLC

Recruiting

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC)

Colitis, Ulcerative

United States, Denmark, Belgium, Austria, Greece, Korea, Republic of, United Kingdom, Israel, Poland, Japan, Hungary, Italy, Germany, Australia, Taiwan, New Zealand, Spain, Norway, China, Switzerland, India, Brazil, Croatia, Netherlands, Eston... and more
Janssen Research & Development, LLC

Recruiting

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease (STAR)

Arthritis, Psoriatic

Italy, Germany, Taiwan, United States, Malaysia, Turkey, Georgia, Canada, Hong Kong, Portugal, Denmark, Israel, Philippines, Thailand, Bulgaria, Australia, Czechia, Hungary, Poland, Russian Federation, Ukraine, Spain, Argentina, United... and more
Janssen Research & Development, LLC

Recruiting

A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years

Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention

United States, United Kingdom, Korea, Republic of, Taiwan, Canada, Denmark, France, Thailand, New Zealand, Spain, China, Israel, Germany, Colombia, Netherlands, Australia, Japan, Sweden, Czechia, Italy
Janssen Research & Development, LLC

Recruiting

A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX)

Arthritis, Psoriatic

Israel, United States, Germany, Taiwan, Korea, Republic of, Malaysia, China, Georgia, Hungary, Poland, Spain, Philippines, Italy, Canada, Bulgaria, Russian Federation, Serbia, Slovenia, Bosnia and Herzegovina, Greece, Ukraine, Cze... and more
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder (SunRISe-2)

Urinary Bladder Neoplasms

Taiwan, United States, Korea, Republic of, Austria, Germany, China, Greece, Italy, Argentina, Belgium, Brazil, Mexico, Russian Federation, Spain, Canada, Czechia, France, Japan, Poland, Portugal, Australia, Hungary, India, Ukraine, Turkey
Janssen Research & Development, LLC

Recruiting

A Study to Evaluate the Effect of Renal Impairment on JNJ-42847922 in Adult Participants

Renal Impairment

United States
Janssen Research & Development, LLC

Recruiting

A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (PALOMA)

Advanced Solid Malignancies

United States, Korea, Republic of, Canada, United Kingdom
Janssen Research & Development, LLC

Recruiting

Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma (MonumenTAL-1)

Hematological Malignancies

United States, Netherlands, Spain, Belgium
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma

Neoplasm

China, Taiwan, Korea, Republic of
Janssen Research & Development, LLC

Active, not recruiting

A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy (GO-VIVA)

Arthritis, Juvenile

United States, Israel, Mexico, South Africa, Canada, Brazil, Argentina, Russian Federation, Chile
Janssen Research & Development, LLC

Active, not recruiting

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (MAGNITUDE)

Castration-Resistant Prostatic Cancer

United States, China, Italy, Korea, Republic of, Taiwan, Australia, Sweden, Belgium, Canada, France, Hungary, Israel, Malaysia, Russian Federation, Portugal, Germany, Bulgaria, Spain, Netherlands, Turkey, United Kingdom, Ukraine, Po... and more
Janssen Research & Development, LLC

Active, not recruiting

Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma

Multiple Myeloma

United Kingdom, United States, France, Netherlands, Denmark
Janssen Research & Development, LLC

Active, not recruiting

A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (QUEST)

Prostatic Neoplasms, Castration-Resistant

Belgium, United States, United Kingdom, Canada, Israel, Spain, Italy
Janssen Research & Development, LLC

Active, not recruiting

A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health

Extraintestinal Pathogenic Escherichia Coli Prevention

United States, France, Belgium, Spain, Netherlands
Janssen Research & Development, LLC

Completed

A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection

Hepatitis B, Chronic

France, Taiwan, Canada, United States, Germany, Spain, Japan, Russian Federation, Turkey, United Kingdom
Janssen Research & Development, LLC

Active, not recruiting

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (AMPLITUDE)

Metastatic Castration-sensitive Prostate Cancer

United States, Italy, China, Korea, Republic of, Canada, Australia, United Kingdom, Hungary, France, Taiwan, Thailand, Germany, Malaysia, Denmark, Russian Federation, New Zealand, Ukraine, Bulgaria, Israel, Spain, Turkey, Sweden, Cz... and more
Janssen Research & Development, LLC

Active, not recruiting

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (CHRYSALIS)

Non-Small-Cell Lung Cancer

United States, France, Taiwan, United Kingdom, China, Spain, Japan, Australia, Korea, Republic of, Canada
Janssen Research & Development, LLC

Active, not recruiting

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4)

Multiple Myeloma

United States, Netherlands, Belgium, Korea, Republic of, United Kingdom, Sweden, Denmark, Italy, Japan, Germany, France, Spain, Australia, Israel, Poland, Greece

Clinical Trials Sponsored by JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations